Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
eli lilly
16
×
fda
16
×
life sciences
national blog main
new york blog main
raleigh-durham blog main
san diego blog main
san francisco blog main
seattle blog main
16
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
national
national top stories
new york top stories
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana top stories
biotech
clinical trials
startups
amgen
cancer
pfizer
bristol-myers squibb
deals
glaxosmithkline
medicare
allergan
cancer immunotherapy
What
bio
roundup
drug
companies
drugs
fda
new
week
crispr
days
life
science
won
alzheimer’s
annual
approval
big
biotech
black
class
congress
diabetes
diamond’s
fallout
growing
known
migraine
moves
news
notes
pharma
pharmaceutical
price
thanks
time
administration
airport
alliance
amgen
angry
Language
unset
Current search:
fda
×
" seattle blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines